New treatment option for adult-onset limbal xanthogranuloma

Cornea. 2010 Jan;29(1):113-6. doi: 10.1097/ICO.0b013e3181a06efa.

Abstract

Purpose: The purposes of this study are to report a case of adult-onset juvenile xanthogranuloma and suggest a new treatment option.

Methods: A 35-year-old man presented with an isolated mass of the limbus. Biopsy revealed a histiocytic tumor with Touton's giant cells staining positive for CD68 and S-100 but negative for CD1a, consistent with JXG. Two intratumoral injections of triamcinolone acetonide 6 weeks apart were performed. The main outcome measure was 6-months follow up clinically and by ultrasound biomicroscopy.

Results: The lesion regressed, and corneal thickness returned to normal 3 months after the first injection. An increase in intraocular pressure required topical treatment. No recurrence was seen throughout follow up.

Conclusion: Limbal juvenile xanthogranuloma can be successfully treated with intralesional triamcinolone acetonide, thus avoiding a lamellar keratectomy approach.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / metabolism
  • Corneal Diseases / pathology
  • Follow-Up Studies
  • Glucocorticoids / therapeutic use*
  • Humans
  • Injections, Intralesional
  • Limbus Corneae / pathology*
  • Male
  • Triamcinolone Acetonide / therapeutic use*
  • Xanthogranuloma, Juvenile / drug therapy*
  • Xanthogranuloma, Juvenile / metabolism
  • Xanthogranuloma, Juvenile / pathology

Substances

  • Biomarkers
  • Glucocorticoids
  • Triamcinolone Acetonide